Antiemetic efficacy of granisetron

A randomized crossover study in patients receiving cisplatin-containing intraarterial chemotherapy

Katsunori Uchida, Hideyuki Akaza, Kazunori Hattori, Ryosuke Noguchi, Fukuji Kondo, Satoru Ishikawa, Mikinobu Ohtani, Shiro Hinotsu, Kenkichi Koiso

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Cisplatin (CDDP) is one of the most active chemotherapeutic agents but is among the most emetogenic drugs. The emetic side-effects of CDDP-containing intraarterial chemotherapy have not been evaluated in a prospective randomized trial and the efficacy of serotonin antagonists in preventing the emesis associated with this method of CDDP administration has not been assessed. Methods: CDDP 50 mg/m2 and methotrexate 30 mg/m2 were administered every 3 weeks through intraarterial catheters placed in the bilateral internal iliac arteries. Patients were classified into two groups: granisetron treatment group (group G) and no treatment group (group NG) with the first course of chemotherapy, crossing over with the second course. The patients in group G received granisetron 40 μg/kg by intravenous infusion. Results: Although intraarterial CDDP administration produced less emesis than intravenous CDDP administration, at the same concentration, gastrointestinal toxicity is still the most unpleasant side-effect for patients. Granisetron administration significantly reduced nausea and vomiting during the acute emetic phase (an evaluation of treatment as very effective and effective was made in 89% in group G and 33% in group NG (P <0.001). Complete control of emesis was achieved in 68 and 18% of patients in groups G and NG, respectively (P <0.0001). Conclusion: A single prophylactic infusion of granisetron was effective in preventing the nausea and vomiting associated with intraarterial CDDP-containing therapy.

Original languageEnglish
Pages (from-to)87-91
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume29
Issue number2
Publication statusPublished - Feb 1999
Externally publishedYes

Fingerprint

Granisetron
Antiemetics
Cross-Over Studies
Cisplatin
Vomiting
Drug Therapy
Emetics
Nausea
Serotonin Antagonists
Iliac Artery
Therapeutics
Intravenous Infusions
Methotrexate
Intravenous Administration
Catheters
Pharmaceutical Preparations

Keywords

  • Anti-emetic efficacy
  • Bladder cancer
  • Cisplatin
  • Crossover trial
  • Granisetron
  • Intra-arterial chemotherapy

ASJC Scopus subject areas

  • Oncology

Cite this

Uchida, K., Akaza, H., Hattori, K., Noguchi, R., Kondo, F., Ishikawa, S., ... Koiso, K. (1999). Antiemetic efficacy of granisetron: A randomized crossover study in patients receiving cisplatin-containing intraarterial chemotherapy. Japanese Journal of Clinical Oncology, 29(2), 87-91.

Antiemetic efficacy of granisetron : A randomized crossover study in patients receiving cisplatin-containing intraarterial chemotherapy. / Uchida, Katsunori; Akaza, Hideyuki; Hattori, Kazunori; Noguchi, Ryosuke; Kondo, Fukuji; Ishikawa, Satoru; Ohtani, Mikinobu; Hinotsu, Shiro; Koiso, Kenkichi.

In: Japanese Journal of Clinical Oncology, Vol. 29, No. 2, 02.1999, p. 87-91.

Research output: Contribution to journalArticle

Uchida, K, Akaza, H, Hattori, K, Noguchi, R, Kondo, F, Ishikawa, S, Ohtani, M, Hinotsu, S & Koiso, K 1999, 'Antiemetic efficacy of granisetron: A randomized crossover study in patients receiving cisplatin-containing intraarterial chemotherapy', Japanese Journal of Clinical Oncology, vol. 29, no. 2, pp. 87-91.
Uchida, Katsunori ; Akaza, Hideyuki ; Hattori, Kazunori ; Noguchi, Ryosuke ; Kondo, Fukuji ; Ishikawa, Satoru ; Ohtani, Mikinobu ; Hinotsu, Shiro ; Koiso, Kenkichi. / Antiemetic efficacy of granisetron : A randomized crossover study in patients receiving cisplatin-containing intraarterial chemotherapy. In: Japanese Journal of Clinical Oncology. 1999 ; Vol. 29, No. 2. pp. 87-91.
@article{6ae48fff8546459baddd1d33f670d287,
title = "Antiemetic efficacy of granisetron: A randomized crossover study in patients receiving cisplatin-containing intraarterial chemotherapy",
abstract = "Background: Cisplatin (CDDP) is one of the most active chemotherapeutic agents but is among the most emetogenic drugs. The emetic side-effects of CDDP-containing intraarterial chemotherapy have not been evaluated in a prospective randomized trial and the efficacy of serotonin antagonists in preventing the emesis associated with this method of CDDP administration has not been assessed. Methods: CDDP 50 mg/m2 and methotrexate 30 mg/m2 were administered every 3 weeks through intraarterial catheters placed in the bilateral internal iliac arteries. Patients were classified into two groups: granisetron treatment group (group G) and no treatment group (group NG) with the first course of chemotherapy, crossing over with the second course. The patients in group G received granisetron 40 μg/kg by intravenous infusion. Results: Although intraarterial CDDP administration produced less emesis than intravenous CDDP administration, at the same concentration, gastrointestinal toxicity is still the most unpleasant side-effect for patients. Granisetron administration significantly reduced nausea and vomiting during the acute emetic phase (an evaluation of treatment as very effective and effective was made in 89{\%} in group G and 33{\%} in group NG (P <0.001). Complete control of emesis was achieved in 68 and 18{\%} of patients in groups G and NG, respectively (P <0.0001). Conclusion: A single prophylactic infusion of granisetron was effective in preventing the nausea and vomiting associated with intraarterial CDDP-containing therapy.",
keywords = "Anti-emetic efficacy, Bladder cancer, Cisplatin, Crossover trial, Granisetron, Intra-arterial chemotherapy",
author = "Katsunori Uchida and Hideyuki Akaza and Kazunori Hattori and Ryosuke Noguchi and Fukuji Kondo and Satoru Ishikawa and Mikinobu Ohtani and Shiro Hinotsu and Kenkichi Koiso",
year = "1999",
month = "2",
language = "English",
volume = "29",
pages = "87--91",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Antiemetic efficacy of granisetron

T2 - A randomized crossover study in patients receiving cisplatin-containing intraarterial chemotherapy

AU - Uchida, Katsunori

AU - Akaza, Hideyuki

AU - Hattori, Kazunori

AU - Noguchi, Ryosuke

AU - Kondo, Fukuji

AU - Ishikawa, Satoru

AU - Ohtani, Mikinobu

AU - Hinotsu, Shiro

AU - Koiso, Kenkichi

PY - 1999/2

Y1 - 1999/2

N2 - Background: Cisplatin (CDDP) is one of the most active chemotherapeutic agents but is among the most emetogenic drugs. The emetic side-effects of CDDP-containing intraarterial chemotherapy have not been evaluated in a prospective randomized trial and the efficacy of serotonin antagonists in preventing the emesis associated with this method of CDDP administration has not been assessed. Methods: CDDP 50 mg/m2 and methotrexate 30 mg/m2 were administered every 3 weeks through intraarterial catheters placed in the bilateral internal iliac arteries. Patients were classified into two groups: granisetron treatment group (group G) and no treatment group (group NG) with the first course of chemotherapy, crossing over with the second course. The patients in group G received granisetron 40 μg/kg by intravenous infusion. Results: Although intraarterial CDDP administration produced less emesis than intravenous CDDP administration, at the same concentration, gastrointestinal toxicity is still the most unpleasant side-effect for patients. Granisetron administration significantly reduced nausea and vomiting during the acute emetic phase (an evaluation of treatment as very effective and effective was made in 89% in group G and 33% in group NG (P <0.001). Complete control of emesis was achieved in 68 and 18% of patients in groups G and NG, respectively (P <0.0001). Conclusion: A single prophylactic infusion of granisetron was effective in preventing the nausea and vomiting associated with intraarterial CDDP-containing therapy.

AB - Background: Cisplatin (CDDP) is one of the most active chemotherapeutic agents but is among the most emetogenic drugs. The emetic side-effects of CDDP-containing intraarterial chemotherapy have not been evaluated in a prospective randomized trial and the efficacy of serotonin antagonists in preventing the emesis associated with this method of CDDP administration has not been assessed. Methods: CDDP 50 mg/m2 and methotrexate 30 mg/m2 were administered every 3 weeks through intraarterial catheters placed in the bilateral internal iliac arteries. Patients were classified into two groups: granisetron treatment group (group G) and no treatment group (group NG) with the first course of chemotherapy, crossing over with the second course. The patients in group G received granisetron 40 μg/kg by intravenous infusion. Results: Although intraarterial CDDP administration produced less emesis than intravenous CDDP administration, at the same concentration, gastrointestinal toxicity is still the most unpleasant side-effect for patients. Granisetron administration significantly reduced nausea and vomiting during the acute emetic phase (an evaluation of treatment as very effective and effective was made in 89% in group G and 33% in group NG (P <0.001). Complete control of emesis was achieved in 68 and 18% of patients in groups G and NG, respectively (P <0.0001). Conclusion: A single prophylactic infusion of granisetron was effective in preventing the nausea and vomiting associated with intraarterial CDDP-containing therapy.

KW - Anti-emetic efficacy

KW - Bladder cancer

KW - Cisplatin

KW - Crossover trial

KW - Granisetron

KW - Intra-arterial chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0033070626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033070626&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 87

EP - 91

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 2

ER -